Trusted Resources: News & Meetings
Latest announcements and gatherings
Experimental MPS 1 Therapy Shows Biomarker Activity, Improved Function
REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I). The data, presented at the 18th annual WORLDSymposium, represented six patients diagnosed with severe MPS I who were treated with RGX-111.
Mucopolysaccharidosis Type I is a rare, genetic condition that can affect many parts of the body. The condition stems from a mutation in the IDUA gene which provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules. In people with MPS I, the gene reduces or completely eliminates the enzymes needed for the breakdown of large sugar molecules, leading to the accumulation of these molecules in cells called lysosomes, whose function is to digest and recycle molecules. The lysosomes become enlarged, causing significant issues in multiple organs including decline in central nervous system (CNS) functioning.
BookmarkRelated Content
-
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th ...REGENXBIO Inc. (Nasdaq: RGNX) today anno...
-
Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VIIVestronidase alfa is an enzyme replaceme...
-
Long-Term Evolution of Mucopolysaccharidosis Type I in Twins Treated With Enzyme Replacement Therapy Plus Hematopoie...Mucopolysaccharidoses (MPSs) are a heter...
-
New Type A ERT Candidate on Track for Clinical TrialJapanese company, JCR Pharmaceuticals, h...
-
Gene Therapy for Sanfilippo: Where We Are NowGene therapy is a promising approach for...
-
Mount Sinai – Lysosomal Storage Disease ProgramThe Mount Sinai Hospital’s Lysosomal S...
-
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler SyndromeAllogeneic hematopoietic stem-cell trans...
Powered by
